This company has been marked as potentially delisted and may not be actively trading. HeartBeam (BEAT) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesShort InterestTrendsBuy This Stock BEAT vs. SGHT, OSUR, DRTS, BWAY, PROF, TLSI, SKIN, GCTK, UTMD, and ANIKShould you be buying HeartBeam stock or one of its competitors? The main competitors of HeartBeam include Sight Sciences (SGHT), OraSure Technologies (OSUR), Alpha Tau Medical (DRTS), BrainsWay (BWAY), Profound Medical (PROF), TriSalus Life Sciences (TLSI), Beauty Health (SKIN), GlucoTrack (GCTK), Utah Medical Products (UTMD), and Anika Therapeutics (ANIK). These companies are all part of the "medical" sector. HeartBeam vs. Its Competitors Sight Sciences OraSure Technologies Alpha Tau Medical BrainsWay Profound Medical TriSalus Life Sciences Beauty Health GlucoTrack Utah Medical Products Anika Therapeutics Sight Sciences (NASDAQ:SGHT) and HeartBeam (NASDAQ:BEAT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk. Do analysts prefer SGHT or BEAT? Sight Sciences currently has a consensus target price of $4.10, indicating a potential downside of 3.07%. HeartBeam has a consensus target price of $8.00, indicating a potential upside of 465.37%. Given HeartBeam's stronger consensus rating and higher possible upside, analysts clearly believe HeartBeam is more favorable than Sight Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sight Sciences 0 Sell rating(s) 5 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.29HeartBeam 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better earnings and valuation, SGHT or BEAT? HeartBeam has lower revenue, but higher earnings than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than HeartBeam, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSight Sciences$78.11M2.80-$51.51M-$0.98-4.32HeartBeamN/AN/A-$19.45M-$0.68-2.08 Does the media prefer SGHT or BEAT? In the previous week, HeartBeam had 1 more articles in the media than Sight Sciences. MarketBeat recorded 3 mentions for HeartBeam and 2 mentions for Sight Sciences. Sight Sciences' average media sentiment score of 1.10 beat HeartBeam's score of 0.00 indicating that Sight Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sight Sciences 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive HeartBeam 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, SGHT or BEAT? Sight Sciences has a beta of 2.46, meaning that its share price is 146% more volatile than the S&P 500. Comparatively, HeartBeam has a beta of -0.59, meaning that its share price is 159% less volatile than the S&P 500. Do insiders & institutionals believe in SGHT or BEAT? 55.5% of Sight Sciences shares are owned by institutional investors. Comparatively, 7.8% of HeartBeam shares are owned by institutional investors. 28.9% of Sight Sciences shares are owned by company insiders. Comparatively, 18.0% of HeartBeam shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is SGHT or BEAT more profitable? HeartBeam has a net margin of 0.00% compared to Sight Sciences' net margin of -63.24%. Sight Sciences' return on equity of -54.62% beat HeartBeam's return on equity.Company Net Margins Return on Equity Return on Assets Sight Sciences-63.24% -54.62% -34.92% HeartBeam N/A -358.33%-278.76% SummarySight Sciences beats HeartBeam on 8 of the 15 factors compared between the two stocks. Get HeartBeam News Delivered to You Automatically Sign up to receive the latest news and ratings for BEAT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BEAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BEAT vs. The Competition Export to ExcelMetricHeartBeamMEDICAL INFO SYS IndustryMedical SectorNASDAQ ExchangeMarket Cap$49.70M$2.01B$5.21B$8.73BDividend YieldN/AN/A5.38%4.23%P/E Ratio-1.9937.6625.1419.41Price / SalesN/A16.24395.78117.11Price / CashN/A53.9435.5255.95Price / Book23.589.158.005.48Net Income-$19.45M-$63.71M$3.15B$248.27M HeartBeam Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BEATHeartBeam1.4144 of 5 stars$1.42-32.3%$8.00+465.4%-39.5%$49.70MN/A-1.991,700Gap UpSGHTSight Sciences1.4069 of 5 stars$4.22+0.2%$4.02-4.8%-31.0%$218.16M$78.11M-4.14210News CoveragePositive NewsOSUROraSure Technologies1.1529 of 5 stars$2.92+1.2%$3.00+2.9%-29.9%$218.04M$161.63M19.43840DRTSAlpha Tau Medical2.7851 of 5 stars$2.95-1.7%$8.00+171.2%+35.3%$207.62MN/A-6.8680Positive NewsBWAYBrainsWay2.026 of 5 stars$10.88-1.7%$14.25+31.0%+90.1%$205.35M$43.46M108.76120News CoverageGap UpPROFProfound Medical2.2043 of 5 stars$6.77-0.2%$11.50+70.0%-28.0%$203.31M$11.86M-5.05150News CoverageTLSITriSalus Life Sciences3.0968 of 5 stars$5.34-3.1%$10.75+101.3%-10.1%$202.06M$32.14M-2.14106Gap DownSKINBeauty Health0.4091 of 5 stars$1.55+0.3%$1.42-8.3%+6.7%$194.66M$322.47M-3.681,030GCTKGlucoTrack0.3693 of 5 stars$6.26-0.7%N/A-99.8%$179.31MN/A-0.115News CoverageGap UpTrading HaltedUTMDUtah Medical Products1.5444 of 5 stars$54.07-1.8%N/A-16.3%$175.62M$39.27M13.69180ANIKAnika Therapeutics3.6493 of 5 stars$11.23+1.1%$20.00+78.1%-56.7%$161.15M$117.05M-1.69300News Coverage Related Companies and Tools Related Companies Sight Sciences Alternatives OraSure Technologies Alternatives Alpha Tau Medical Alternatives BrainsWay Alternatives Profound Medical Alternatives TriSalus Life Sciences Alternatives Beauty Health Alternatives GlucoTrack Alternatives Utah Medical Products Alternatives Anika Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BEAT) was last updated on 6/25/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HeartBeam, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share HeartBeam With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
